May 2026 | Melanoma Monday is 4 May
Skin Cancer Awareness Month: Activate DermaSensor in May with Zero Setup Fee
The first automated skin cancer device for Primary Care Physicians. The only FDA Breakthrough skin cancer detection device designed for PCPs. Start DermaSensor this May and pay no setup or activation fee when your practice qualifies.
Melanoma Monday kicks off the month. Make sure your practice is ready.
Melanoma Monday, observed on the first Monday of May, marks the official start of Skin Cancer Awareness Month in the United States. Patient interest in skin checks is highest during the first week of May. Getting your DermaSensor device before Melanoma Monday lets you assess suspicious lesions right in the exam room, rather than routing every concerning spot into the dermatology referral queue.
Your patients are already Googling their suspicious lesions. With DermaSensor, you can give them a confident answer.
One in five Americans will develop skin cancer by the age of 70,¹ yet only 15% of high-risk Americans have ever been screened for skin cancer, and 40% of Americans face scarce dermatological services.²
Primary care is where that gap gets closed, or missed. Primary care providers have demonstrable difficulty in identifying skin lesions in need of further evaluation, and a routine visit rarely includes a dermatoscope or specialist training.
Skin Cancer Awareness Month is the moment of highest patient awareness and physician opportunity in the calendar year, and the moment DermaSensor was built for.
An objective risk result in the exam room means you can monitor, investigate further, or refer with confidence, during the visit, not after it.
A visual assessment followed by a dermatology referral that can take five weeks or longer is not the answer patients are looking for.
DermaSensor provides an objective, real-time result, transforming the conversation in the moment. Instead of uncertainty, you can decide: monitor or refer with confidence, during the visit, not after it.
Learn More about
Bring specialist-level confidence into your exam room.
You are often the first clinician a patient will show a suspicious lesion to, and short appointments without a dermatoscope or extensive specialty training mean cancers can be missed and many unnecessary referrals can be made.
In the DERM-SUCCESS pivotal study, PCPs correctly referred 91.4% of malignant lesions when aided by the device, compared to just 82.0% without it - a 52% reduction in missed cancer referrals (from 18.0% to 8.6%)2. Their overall management accuracy also increased, so the PCPs became better doctors with the device, not just more conservative doctors.
That is the gap DermaSensor aims to close, and Skin Cancer Awareness Month is when patients most rely on you.
Start in May. Pay no setup or activation fee, just a low monthly subscription
Activate DermaSensor during Skin Cancer Awareness Month, and the one-time setup and activation fee is waived for qualifying practices. You start on a low monthly subscription, and there is no hardware purchase. No hours of training needed or certification course. Just a quick onboarding with a DermaSensor clinical expert and digital tools to help you with your success in offering DermaSensor in your clinic.
What is included in your DermaSensor:- Zero setup and activation fee for qualifying practices
- One DermaSensor handheld device on a monthly subscription basis
- Remote onboarding with a DermaSensor clinical expert
- Access to the DermaSensor patient education resource center
- On-demand customer support and e-learning courses for you and your employees
- Free 3rd party reimbursement guidance
Clinically proven and validated in real-world practice
device sensitivity for detecting all skin cancers across Fitzpatrick skin types2
Reduction in missed cancer referrals (from 18.0% to 8.6%)2. PCPs correctly referred 91.4% of malignant lesions when aided by the device, compared to just 82.0% without it.
of the study physicians agreed the device added value to their clinical care4
agreed it would help detect more skin cancers4
reported increased confidence in evaluating skin lesions4
See DermaSensor in a real clinical workflow
Learn More about
A complete solution set to power your practice
- DermaSensor patient education resource center - customizable materials tailored to your practice
- Physician finder - helps elevate your practice and unlock new patient opportunities
- E-learning courses - free access for you and your employees
- Remote device monitoring - device functionality assessed remotely by our support team
- On-demand customer support
- Accessories included: charging dock, power supply, and regional power adapter blades
- DermaSensor portal for device usage logs and results
- One-click software updates directly to your DermaSensor
- Free 3rd-party reimbursement guidance
Who DermaSensor is for
DermaSensor is a medical device intended for use only by healthcare professionals in clinical settings. The device is designed for use by physicians who are not dermatologists, to aid in clinical decision-making to refer a patient to a dermatologist or not. It is not intended for consumer or at-home use.
DermaSensor - Skin Cancer Awareness Month - FAQs
Skin Cancer Awareness Month - Frequently Asked Questions
When is Skin Cancer Awareness Month, and when is Melanoma Monday 2026?
Skin Cancer Awareness Month is observed throughout May in the United States. Melanoma Monday 2026 falls on 4 May, the first Monday of the month, and marks the official start of awareness activities in clinics and communities.
What does the DermaSensor May 2026 offer include?
Qualifying primary care practices that activate DermaSensor between 1 May and 31 May 2026 pay no one-time setup or activation fee. Practices can start immediately on a monthly subscription with remote onboarding for the clinical team.
Is DermaSensor available as a subscription, or does my practice need to purchase the device?
DermaSensor is provided on a monthly subscription basis. There is no hardware purchase and no capital expenditure. The device remains the property of DermaSensor and is returned if a practice chooses to end the subscription.
How long does it take to start using DermaSensor after activation?
Most practices are scanning patients immediately after activation. Onboarding is a remote session, and there is no certification course required to use the device.
Can my practice bill for DermaSensor skin cancer assessments?
Unlisted CPT code options to consider for DermaSensor services include 96999 (unlisted special dermatological service or procedure) and 17999 (unlisted procedure; skin, mucous membrane, and subcutaneous tissue). Reimbursement varies by payer and region. It is the responsibility of the rendering provider to determine and report appropriate codes, modifiers, and charges for health care services rendered to patients in their care .DermaSensor offers free 3rd party reimbursement guidance.
Indications for Use
The DermaSensor device is indicated for evaluating skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in patients aged 40 and above, to assist in the decision to refer the patient to a dermatologist. The DermaSensor device should be used in conjunction with the totality of clinically relevant information from the clinical assessment, including visual analysis of the lesion, by physicians who are not dermatologists. The device should be used on lesions already assessed as suspicious for skin cancer and not as a screening tool. The device should not be used as the sole diagnostic criterion nor to confirm clinical diagnosis of skin cancer.
Offer terms
Skin Cancer Awareness Month offer applies to new qualifying primary care practice activations between 1 May 2026 and 31 May 2026. Subscription terms and eligibility apply.
References
- Skin Cancer Foundation. Skin Cancer Facts & Statistics. https://www.skincancer.org/skin-cancer-information/skin-cancer-facts/
(As cited in: Dhaliwal et al., Validation of a Handheld Elastic Scattering Spectroscopy Device on Lesions Concerning for Melanoma.)
- Ferris LK, Jaklitsch E, Seiverling EV, et al. DERM-SUCCESS FDA Pivotal Study: A Multi-Reader Multi-Case Evaluation of Primary Care Physicians’ Skin Cancer Detection Using AI-Enabled Elastic Scattering Spectroscopy. J Prim Care Community Health. 2025;16:21501319251342106. https://journals.sagepub.com/doi/full/10.1177/21501319251342106
- Seiverling EV, et al. Clinical Utility of an Elastic Scattering Spectroscopy Device in Assisting Primary Care Physicians’ Detection of Skin Cancers. Poster Presentation, Maui Derm Hawaii Conference, Wailea, HI, January 24–28, 2023.
- Seiverling, E.V. (2025). JCAD MRMC Study. Journal of Clinical and Aesthetic Dermatology, October 2025, 58-65. https://jcadonline.com/enhancing-diagnostic-precision-melanoma-evaluation/